Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration
Paris (France) - Onxeo S.A., a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in part...




